Display options
Cite
Fettke H, Kwan EM, Bukczynska P, et al. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2020;7(6):1287-1291doi: 10.1016/j.euf.2020.07.001.
Fettke, H., Kwan, E. M., Bukczynska, P., Ng, N., Nguyen-Dumont, T., Southey, M. C., Davis, I. D., Mant, A., Parente, P., Pezaro, C., Hauser, C., & Azad, A. A. (2021). Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer. European urology focus, 7(6), 1287-1291. https://doi.org/10.1016/j.euf.2020.07.001
Fettke, Heidi, et al. "Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer." European urology focus vol. 7,6 (2021): 1287-1291. doi: https://doi.org/10.1016/j.euf.2020.07.001
Fettke H, Kwan EM, Bukczynska P, Ng N, Nguyen-Dumont T, Southey MC, Davis ID, Mant A, Parente P, Pezaro C, Hauser C, Azad AA. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2021 Nov;7(6):1287-1291. doi: 10.1016/j.euf.2020.07.001. Epub 2020 Jul 29. PMID: 32739405.
Copy Download .nbib Format: NLM
Share it on

Eur Urol Focus. 2021 Nov;7(6):1287-1291. doi: 10.1016/j.euf.2020.07.001. Epub 2020 Jul 29.

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

European urology focus

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C Southey, Ian D Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A Azad

Affiliations

  1. Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
  2. Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Department of Medical Oncology, Monash Health, Clayton, VIC, Australia.
  3. Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  4. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  5. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  6. Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  7. Medical Oncology Unit, Eastern Health, Box Hill, VIC, Australia; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  8. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England.
  9. Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: [email protected].

PMID: 32739405 DOI: 10.1016/j.euf.2020.07.001

Abstract

Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). However, whether cfDNA concentration is predictive of treatment outcomes with androgen receptor pathway inhibitors (ARPIs) is unknown. We quantified plasma cfDNA levels at baseline (n = 74) and 4 weeks on treatment (n = 56) in a prospective cohort of mCRPC patients treated with the ARPIs abiraterone acetate or enzalutamide. Elevated total cfDNA concentration (log

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Keywords: Abiraterone; Androgen receptor pathway inhibitor; Biomarker; Castrate resistant; Cell-free DNA; Enzalutamide; Liquid biopsy; Prostate cancer

Publication Types